Treatment Outcomes with Hypomethylating Agents and Venetoclax for AML in the Community Compared to an Academic Setting

被引：0
|
作者：
Jeffrey, Lantz, Jr. [1 ]
Pham, Natalie [2 ]
Jones, Caroline [3 ]
Kundu, Debamita [4 ]
McCann, Nicholas [5 ]
El Chaer, Firas [1 ]
Reed, Daniel [1 ]
Keng, Michael [1 ]
机构：
[1] Univ Virginia, Div Hematol & Oncol, Dept Med, Comprehens Canc Ctr,Med Ctr, Charlottesville, VA USA
[2] Univ Virginia, Dept Med, Med Ctr, Charlottesville, VA USA
[3] Univ Virginia, Dept Pharm, Med Ctr, Charlottesville, VA USA
[4] Univ Virginia, Div Biostat, Charlottesville, VA USA
[5] Univ Virginia, Sch Med, Charlottesville, VA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190176
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Niscola, Pasquale
    Gianfelici, Valentina
    Giovannini, Marco
    Piccioni, Daniela
    Mazzone, Carla
    de Fabritiis, Paolo
    ANNALS OF HEMATOLOGY, 2024, 103 (05) : 1787 - 1788
  • [32] Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Pasquale Niscola
    Valentina Gianfelici
    Marco Giovannini
    Daniela Piccioni
    Carla Mazzone
    Paolo de Fabritiis
    Annals of Hematology, 2024, 103 : 1787 - 1788
  • [33] Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax
    Chen, Evan C.
    Liu, Yiwen
    Winer, Eric S.
    Luskin, Marlise R.
    Wadleigh, Martha
    Lane, Andrew A.
    Vedula, Rahul S.
    Lindsley, Coleman
    Copson, Kevin
    Charles, Anne
    Neuberg, Donna S.
    Issa, Nicolas C.
    DeAngelo, Daniel J.
    Stone, Richard M.
    Garcia, Jacqueline S.
    BLOOD, 2021, 138
  • [34] Survival Outcomes Associated with Molecular and Cytogenetic Alterations in AML Patients Treated with Hypomethylating Agent and Venetoclax
    Boisclair, Stephanie
    Naing, Phyu Thin
    Zhou, Edward
    Thakur, Richa
    Goldberg, Bradley
    Jou, Erin
    Chitty, David W.
    Kolitz, Jonathan E.
    BLOOD, 2023, 142
  • [35] Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Berton, Guillaume
    Schaefer, Eva J.
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Bystrom, Rebecca P.
    Lindsley, R. Coleman
    Chen, Evan C.
    Perez, Jorge Ramos
    Stein, Anthony
    Pullarkat, Vinod
    Aldoss, Ibrahim
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Garciaz, Sylvain
    Ball, Brian
    Stahl, Maximilian
    BLOOD ADVANCES, 2024, 8 (18) : 4845 - 4855
  • [36] Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions
    Chin, Kuo-Kai
    Derkach, Andriy
    Famulare, Christopher
    Gupta, Gaurav
    Borge, Prabhakar
    Berman, Ellin
    Geyer, Mark Blaine
    Goldberg, Aaron D.
    Haque, Tamanna
    Rampal, Raajit K.
    Park, Jae H.
    Roeker, Lindsey E.
    Tallman, Martin S.
    Stein, Eytan M.
    BLOOD, 2023, 142
  • [37] Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes
    Ghorab, Ahmad
    Litzow, Mark
    Gangat, Naseema
    Al-Kali, Aref
    Shah, Mithun
    Murthy, Hemant
    Alkhateeb, Hasan
    Begna, Kebede
    Patnaik, Mrinal
    Foran, James
    Badar, Talha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S306 - S306
  • [38] Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/ Refractory Acute Myeloid Leukemia
    Mohassel, Leila
    Yakubi, Hanna
    Jones, Kendra
    Wang, Hongkun
    Shafer, Danielle
    BLOOD, 2022, 140 : 6158 - 6159
  • [39] Real-World Safety and Health Care Resource Utilization Analysis of Venetoclax and Hypomethylating-Agent Treatment for AML in an Academic-Affiliated Urban Community Oncology Network
    Carlson, Sophie G.
    Boiarsky, Jonathan
    Daniel, Claire E.
    Gaut, Daria
    Cascavita, Catherine
    Lam, Christine
    Doyel, Michael
    Schiller, Gary J.
    Chai-Ho, Wanxing
    BLOOD, 2022, 140 : 13282 - 13284
  • [40] Treatment of Low-Blast Count AML using Hypomethylating Agents
    De Bellis, Eleonora
    Fianchi, Luana
    Buccisano, Francesco
    Criscuolo, Marianna
    Maurillo, Luca
    Cicconi, Laura
    Brescini, Mattia
    Del Principe, Maria Ilaria
    Di Veroli, Ambra
    Venditti, Adriano
    Amadori, Sergio
    Arcese, William
    Lo-Coco, Francesco
    Voso, Maria Teresa
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2017, 9
12345